Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy

Hepatitis B virus (HBV) core antigen antibodies passively transferred from immunoglobulin products used for replacement or immunomodulation may lead to unnecessary antiviral treatment for patients who are also starting immunosuppressive treatment. We have systematically assessed the contents of 93 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindahl, Hannes, Norlin, Anna-Carin, Bergman, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644822/
https://www.ncbi.nlm.nih.gov/pubmed/38023555
http://dx.doi.org/10.1093/ofid/ofad551
_version_ 1785147288750915584
author Lindahl, Hannes
Norlin, Anna-Carin
Bergman, Peter
author_facet Lindahl, Hannes
Norlin, Anna-Carin
Bergman, Peter
author_sort Lindahl, Hannes
collection PubMed
description Hepatitis B virus (HBV) core antigen antibodies passively transferred from immunoglobulin products used for replacement or immunomodulation may lead to unnecessary antiviral treatment for patients who are also starting immunosuppressive treatment. We have systematically assessed the contents of 93 commercial immunoglobulin batches and show that there are consistent product-specific differences in the levels of HBV core antigen antibodies and that choice of immunoglobulin product may have an impact on false-positivity rates.
format Online
Article
Text
id pubmed-10644822
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106448222023-11-14 Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy Lindahl, Hannes Norlin, Anna-Carin Bergman, Peter Open Forum Infect Dis Brief Report Hepatitis B virus (HBV) core antigen antibodies passively transferred from immunoglobulin products used for replacement or immunomodulation may lead to unnecessary antiviral treatment for patients who are also starting immunosuppressive treatment. We have systematically assessed the contents of 93 commercial immunoglobulin batches and show that there are consistent product-specific differences in the levels of HBV core antigen antibodies and that choice of immunoglobulin product may have an impact on false-positivity rates. Oxford University Press 2023-11-14 /pmc/articles/PMC10644822/ /pubmed/38023555 http://dx.doi.org/10.1093/ofid/ofad551 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Lindahl, Hannes
Norlin, Anna-Carin
Bergman, Peter
Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy
title Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy
title_full Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy
title_fullStr Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy
title_full_unstemmed Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy
title_short Product Choice Affects Risk of False-Positive Hepatitis B Virus Serology During Immunoglobulin Replacement Therapy
title_sort product choice affects risk of false-positive hepatitis b virus serology during immunoglobulin replacement therapy
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644822/
https://www.ncbi.nlm.nih.gov/pubmed/38023555
http://dx.doi.org/10.1093/ofid/ofad551
work_keys_str_mv AT lindahlhannes productchoiceaffectsriskoffalsepositivehepatitisbvirusserologyduringimmunoglobulinreplacementtherapy
AT norlinannacarin productchoiceaffectsriskoffalsepositivehepatitisbvirusserologyduringimmunoglobulinreplacementtherapy
AT bergmanpeter productchoiceaffectsriskoffalsepositivehepatitisbvirusserologyduringimmunoglobulinreplacementtherapy

Ejemplares similares